Immuno-Oncology and the Role of Biomarkers, Companion and Complementary Diagnostics
The recent evolution of immunotherapies and their potential applications have greatly impacted patients’ options for effective oncology treatments. These advances have been powered in part by the use of a variety of biomarkers, companion diagnostics (CDx) and complementary diagnostics.
Having supported immuno-oncology drug development from preclinical studies to clinical trials, and post-market introduction of the therapy and associated diagnostics, global contract research organizations (CROs) like Covance have a unique perspective on the novel developments in this field. This whitepaper shares some of the highlights in personalized medicine Covance has supported recently as new immuno-oncology therapies have emerged.
In this white paper, you’ll learn about:
- Programmed death-ligand 1 (PD-L1) expression patterns, assay formats and method comparison studies
- The current use of companion and complementary diagnostics
- Commercial implications and trends
- Advances and applications for genomic biomarker assays
- Future considerations, from preclinical studies to commercialization of the therapy and relevant diagnostic assays